Business Value: Jyong Biotech Ltd (MENS)

Jyong Biotech Ltd (MENS) is gradually gaining the trust of the medical community as a promising developer of urological treatments. The market capitalization trend on the GURU.Markets platform stands at 156.93, illustrating the position of the company as a creator of plant-based medicines. The business faces stringent regulatory requirements and a shortage of recurring revenue, while its expansion into Asia relies on alliances with regional centers and distributors.

Total Company Value: jyongbio.com (MENS) for 11/23/2025 - 10/30/2026

Jyong Biotech Ltd (MENS) - metric breakdowns and financial figures

- market value and analyst target forecast:

Market Price Jyong Biotech Limited|MENS - Price Target Chart

- company stock exchange capitalization indicators:

Market Capitalization Jyong Biotech|MENS - Total Company Value

- balance sheet net asset value indicators:

Net Assets per Share Jyong Biotech|MENS - Company Book Value|Market Capitalization to Net Assets jyongbio.com|MENS - Company Total Assets

- debt level and financial liquidity data:

- company profitability and valuation multiples indicators:

MENS - Net Income

Analysis of all company metrics:Jyong Biotech Limited

Management at Jyong Biotech Ltd (MENS) is focusing on bringing niche drugs to market and expanding its licensing base. An analysis of the company's total enterprise value allows for the determination of the business's real cost by summing market capitalization and debt minus cash, which helps investors assess the efficiency of drug commercialization relative to the actual cost of acquiring the entire enterprise.

Competitors of Jyong Biotech Ltd (MENS)

Haleon PLC (HLN) - Total Enterprise Value|KVUE - Total Company Value|VRNA (Verona Pharma Inc.) - Business Value|Ligand Pharmaceuticals (LGND) - Total Company Value|AMRX - Company Buyout Price|Total Company Value Perrigo|Alvotech S.A. - Full Business Value|Enterprise Value LQDA|GLPG (Galapagos Corp) - Value Adjusted for Debt and Cash|Enterprise Value ANIP (ANI Pharmaceuticals)|Enterprise Value mannkindcorp.com MNKD|AMPH - Total Company Value|Value Adjusted for Debt and Cash PCRX (Pacira Pharmaceuticals)|ARS Pharma (SPRY) - Total Company Value|Real Price to Acquire Entire Company Theravance Corp|AQST (Aquestive Therapeutics) - Enterprise Value|Enterprise Value scPharma|Real Price to Acquire Entire Company TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharma) - Value Adjusted for Debt and Cash|Total Company Value China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Total Enterprise Value|BHST: Real Price to Acquire Entire Company|invizyne.com - Aggregate Business Value|ORMP: Enterprise Value|Entera Bio - Value Adjusted for Debt and Cash|HYFT (MindWalk) - Enterprise Value|Total Enterprise Value ABVC BioPharma, Inc ABVC|Total Company Value Cumberland Pharmaceuticals (CPIX)|QNTM (quantumbiopharma.com) - Value Adjusted for Debt and Cash|Total Company Value FibroGen FGEN|Aggregate Business Value TELO (Telomir Pharmaceuticals Inc)|RANI: Real Price to Acquire Entire Company|Total Enterprise Value Synergy CHC Corp|rallybio.com (RLYB) - Total Company Value|Total Enterprise Value Lexaria Bioscience Corp. (LEXX)|Total Company Value Pulmatrix|Business Value PTHL (Pheton)|Enterprise Value APM|Lyra Therapeutics Inc (LYRA) - Full Takeover Company Value|Impact BioMedical - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TNFA|cbdMD Corp - Enterprise Value|PRFX: Total Company Value|CYTO: Enterprise Value|LIPO - Company Buyout Price|Total Company Value OptiNose, Inc.|Total Enterprise Value pieris.com PIRS|Real Price to Acquire Entire Company PROC (Procaps)|Aggregate Business Value PTPI|Enterprise Value QLI (Qilian International Holding Group Limited)|ACELYRIN Inc. (SLRN) - Total Enterprise Value|TFF Pharmaceuticals - Enterprise Value